Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00780676 | Personalized Treatment Selection for Metastatic Breast Cancer | terminated | Phase 2 | 97 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT03241810 | Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer(SHERBOC) | terminated | Phase 2 | 22 | Elevation OncologyINDUSTRY | 6 | Sep 2, 2020 | clinicaltrials |
| NCT03430466 | Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer | terminated | Phase 2 | 1 | Kyoto Breast Cancer Research NetworkOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01225172 | Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors | terminated | Phase 2 | 77 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 11, 2020 | clinicaltrials |
| NCT00437294 | Enzastaurin in Combination of Capecitabine to Treat Breast Cancer | terminated | Phase 2 | 86 | Eli Lilly and CompanyINDUSTRY | 5 | Aug 10, 2020 | clinicaltrials |
| NCT00112749 | Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer | terminated | Phase 2 | 7 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02685111 | Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) | terminated | Phase 2 | 22 | Asan Medical CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT00905021 | Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer(EXTENT) | terminated | Phase 1 / Phase 2 | 4 | Baylor Breast Care CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02892734 | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer | terminated | Phase 2 | 3 | Northwestern UniversityOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT00003086 | Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 12 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT02624700 | 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 13 | Virginia Commonwealth UniversityOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT02395627 | Reversing Therapy Resistance With Epigenetic-Immune Modification | terminated | Phase 2 | 38 | University of California, San FranciscoOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02462200 | Shave Margins in Breast Conservation Therapy(SMART) | terminated | Phase 2 | 81 | Washington University School of MedicineOTHER | 1 | Jun 25, 2020 | clinicaltrials |
| NCT02202746 | A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | terminated | Phase 2 | 178 | Clovis Oncology, Inc.INDUSTRY | 1 | Jun 23, 2020 | clinicaltrials |
| NCT01627067 | Exemestane-RAD001-Metformin | terminated | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2020 | clinicaltrials |
| NCT00090480 | Vaccine Treatment for Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 3 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT04066790 | Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | terminated | Phase 2 | 12 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT02774681 | Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis | terminated | Phase 2 | 12 | Northwestern UniversityOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT01060345 | A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ | terminated | Phase 2 | 20 | University of ChicagoOTHER | 1 | Apr 9, 2020 | clinicaltrials |
| NCT03763851 | Cannabis Oil and Radiation Therapy for the Management of Pain | terminated | Phase 2 | 100 | Tetra Bio-PharmaINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT01900730 | Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT00616122 | Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 32 | University of California, San FranciscoOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT01545648 | Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer | terminated | Phase 2 | 4 | Hope Rugo, MDOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01624090 | Mithramycin for Lung, Esophagus, and Other Chest Cancers | terminated | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2019 | clinicaltrials |
| NCT02115048 | Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone | terminated | Phase 2 | 44 | Translational Research in OncologyOTHER | 4 | Dec 26, 2019 | clinicaltrials |
| NCT00574236 | Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer | terminated | Phase 2 | 4 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01902823 | Effect of Cancer Nurse Navigators on Patient Outcomes | terminated | Phase 2 / Phase 3 | 16 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01083641 | Estrogen for Triple Negative Breast Cancer | terminated | Phase 2 | 17 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT02538471 | LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer | terminated | Phase 2 | 3 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00140140 | A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer | terminated | Phase 1 / Phase 2 | 16 | CelgeneINDUSTRY | 1 | Nov 26, 2019 | clinicaltrials |
| NCT00281528 | Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer | terminated | Phase 2 | 208 | CelgeneINDUSTRY | 2 | Nov 22, 2019 | clinicaltrials |
| NCT00456846 | First Line Therapy for Patients With Metastatic Breast Cancer | terminated | Phase 2 | 123 | CelgeneINDUSTRY | 1 | Nov 22, 2019 | clinicaltrials |
| NCT01952054 | Denosumab for Breast Cancer With Bone Mets | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT00531271 | ABI-008 Trial in Patients With Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 85 | CelgeneINDUSTRY | 1 | Nov 14, 2019 | clinicaltrials |
| NCT01118975 | GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers | terminated | Phase 1 / Phase 2 | 12 | University of Maryland, BaltimoreOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02318901 | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer(PembroMab) | terminated | Phase 1 / Phase 2 | 16 | Western Regional Medical CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT02472353 | Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer | terminated | Phase 2 | 30 | Avera McKennan Hospital & University Health CenterOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT02034916 | A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)(ABRAZO) | terminated | Phase 2 | 84 | PfizerINDUSTRY | 5 | Oct 14, 2019 | clinicaltrials |
| NCT01370239 | HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy | terminated | Phase 2 | 23 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Oct 11, 2019 | clinicaltrials |
| NCT02950480 | Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial | terminated | Phase 2 | 4 | University of California, San FranciscoOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01891357 | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer | terminated | Phase 2 | 64 | Women's Cancer Study Group GmbHOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT02598310 | Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer | terminated | Phase 2 | 30 | Osaka Medical CollegeOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT00771381 | A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer | terminated | Phase 2 | 23 | AHS Cancer Control AlbertaOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT02983604 | GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | terminated | Phase 1 / Phase 2 | 14 | Gilead SciencesINDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | terminated | Phase 2 | 3 | Effector TherapeuticsINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Sep 3, 2020source: clinicaltrials